MorphoSys signs agreement with Merck

	Tweet

MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys’s HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.

Under the terms of the agreement, MorphoSys grants Merck access to its proprietary technologies for use in Merck’s drug discovery programs. Furthermore, the agreement enables Merck to develop HuCAL-derived therapeutic antibodies in a range of indications. MorphoSys receives an up-front payment, annual user fees and R&D funding. MorphoSys is also eligible to receive license and milestone payments on projects in clinical development, and royalties on any end-products emerging from the collaboration. Further financial details were not disclosed.

During the term of the agreement, Merck will have access to the MorphoSys HuCAL GOLD antibody library and automated screening system AutoCAL at its research sites. Merck also has access to MorphoSys’s HuCAL EST technology, which enables the rapid generation of human antibodies against newly identified proteins and an option to pursue up to ten HuCAL-based therapeutic antibody programs.

“We expect our agreement with MorphoSys to play a key role in building Merck’s capabilities for developing novel therapeutics in the biologics area” said Dr. John Shiver, Vice President and Head of Merck Vaccines and Biologics Research.

“We are excited to embark upon this technology-based collaboration with a top tier pharma company”, commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. “Our latest collaboration with Merck underscores the value and importance of our technology platform and its potential in pharmaceutical R&D as well as our ability to forge long-term partnerships based on our capabilities in the antibody arena.”

http://www.morphosys.com

RELATED STORIES:
Alfuzosin safe for older patients with cardiovascular disease   Roche aims for 400 million Tamiflu doses by end 2006   Memantine cost-effective for severe Alzheimer’s   Viagra unlikely to trigger heart attack   Glaxo braves fire over HIV drug trials in orphans   FDA OKs Pfizer’s Lipitor for use in diabetics   FDA sets strong warnings for asthma drug labels   New vaccine may help fight leukaemia: study   Hypersensitivity Reactions to the Quadrivalent HPV Vaccine Are Rare   Dutch re-open some farms after dioxin scare   FDA Finds Consumers Continue to Buy Potentially Risky Drugs Over the Internet   Swedish chain challenges state drug sale monopoly

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]